目的 贝伐珠单抗已广泛用于结直肠癌、卵巢癌、宫颈癌、非小细胞肺癌等肿瘤疾病.贝伐珠单抗治疗期间常见药物不良反应包括蛋白尿、血栓、出血、胃肠穿孔和高血压等,其中高血压的发生率高达19％～47％.高血压的发生会影响患者的生活质量,阻碍肿瘤治疗的正常开展,甚至诱发严重心血管疾病,增加死亡风险,需要临床高度重视.本文从贝伐珠单抗相关性高血压的机制、影响因素、预后及相关治疗的研究现状做一综述,为临床合理用药提供参考依据.
Objective Bevacizumab has been clinically used in colorectal cancer,ovarian cancer,cervical cancer,non-small cell lung cancer and other tumor diseases.Common adverse reactions during bevacizumab treatment include albuminuria,thrombosis,bleeding,gastrointestinal perforation and hypertension,among which the incidence of hypertension is as high as 19％-47％.The occurrence of hypertension affects the quality of life of patients,hinds the normal development of tumor treatment,and even induces serious cardiovascular diseases and increases the risk of death,which requires clinical attention.In this paper,the mechanism,influencing factors,prognosis and related treatment of bevacizumab associated hypertension were reviewed,so as to provide reference for clinical rational drug use.
王欢;马松涛;肖洪涛;陈燕;阴骏;徐珂;程凯
成都医学院药学院,四川成都 610500四川省肿瘤临床医学研究中心,四川省肿瘤医院研究所,四川省癌症防治中心,电子科技大学附属肿瘤医院,药学部,四川成都 610041四川省肿瘤临床医学研究中心,四川省肿瘤医院研究所,四川省癌症防治中心,电子科技大学附属肿瘤医院,放疗中心,四川成都 610041
药学
贝伐珠单抗;血管生长因子;抗肿瘤血管生成;药物不良反应;高血压; 预防和治疗
bevacizumab;vascular growth factor;anti-tumor angiogenesis;adverse drug reaction;hypertension;prevention and treatment
《中国临床药理学杂志》 2024 (005)
763-767 / 5
四川省个体化药物治疗重点实验室基金资助项目(2021YB03);中国药学会医院药学专业委员会科研专项基金资助项目(CPA-Z05-ZC-2022-002)
10.13699/j.cnki.1001-6821.2024.05.028
评论